clinical – Page 416 – Communicable Diseases Research

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

The Clinical Characteristics and Prognosis Factors of Mild-Moderate Patients With COVID-19 in a Mobile Cabin Hospital: A Retrospective, Single-Center Study

이동식 오두막 병원에서 COVID-19 경증 환자의 임상 특성 및 예후 인자: 후향적, 단일 센터 연구

Public Health

Published on 2020-06-052022-09-12
Journal: Frontiers in Public Health [Category] MERS, SARS, 진단,

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 A-a gradient acute lung injury acute respiratory distress addition allergic reaction alveolar macrophage alveolar pressure antiviral immunity Antwerp ARDS Belgium blinded Breastfeeding Bruges carbonate clinical clinician Confirmed COVID-19 infection control group Controlled trial COVID-19 COVID-19 pandemic defined Delta dissemination Effect element enrolled enrolment EudraCT ferritin level Ghent GM-CSF granulocyte-macrophage colony-stimulating factor High dose hospital Hypothesis hypoxic failure hypoxic respiratory failure Immune homeostasis inflammatory monocyte Inhaled Intervention intravenous invasive mechanical IWRS system leukine® lung malignancy mechanical ventilation mechanical ventilator Methylprednisolone number objective Open-label outcome oxygen Oxygenation paO2/fiO2 parameters Partial participant Participants Patient PF ratio pregnant primary endpoint progression of disease promote Protein protocol randomised randomised controlled trial randomization Randomized reached receive recruitment Registered Repair mechanisms replaced Respiratory failure Roeselare Sample size sargramostim SpO2 standard care Standard of care status Study protocol supplemental oxygen Support syndrome therapy treat Treatment Trial university ventilatory support Version website were excluded White blood cell
[DOI] 10.1186/s13063-020-04451-7 PMC 바로가기 [Article Type] Letter

A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People’s Hospital, Zhengzhou, China

Medicine

Published on 2020-06-052022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] abnormal hemoglobin activated addition albumin Antibiotic therapy Antibiotics blood biochemistry cardiovascular disease characteristics of patient China clinical Clinical characteristics close contact Coagulation Concentration Confirmed COVID-19 infection coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 cases D-dimer died digestive disease epidemiological Epidemiology evaluated Fever Follow-up ground-glass opacity healthcare facility Immunoglobulin infection markers interleukin-6 lymphocyte mechanical ventilation median age Most patient mottling neutrophil Older one patient Oxygen therapy Patient patients with moderate presenting symptom profiles Retrospective study SARS-CoV-2 severe COVID-19 severe disease Significant significantly sputum production Supplemental oxygen therapy the patient Traditional Chinese medicine transferred type 2 diabete underlying condition underlying disease White blood cell with mild disease X-ray
[DOI] 10.3389/fmed.2020.00286 PMC 바로가기 [Article Type] Medicine

Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections

Microbiology

Published on 2020-06-052022-10-31
Journal: Frontiers in Microbiology [Category] COVID-19,

[키워드] ACE2 acute respiratory distress acute respiratory syndrome Analysis angiotensin-converting enzyme 2 antiviral immunity association Bacteria caused change changes in clinical clinical feature Clinical features coronavirus Coronavirus disease 2019 correlated COVID-19 COVID-19 patients determine Diagnosis digestive tract distribution ENhance Fatality rate gut microbiota help host cells identity immune cells immunopathology infect infecting interferon intestinal tract intestine lung microbial microbiota much lower nucleotide sequence outcome outcomes pandemic Patient peptides Potential predict receptor regulate respiratory virus SARS-CoV SARS-CoV-2 SARS-COV-2 infection SCFAs secretion syndrome Therapies Treatment turn value
[DOI] 10.3389/fmicb.2020.01302 PMC 바로가기 [Article Type] Microbiology

Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial

Letter

Published on 2020-06-042022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour acute COVID-19 administration Anti-inflammatory ARDS block Blood blood cell Cell cells clinical Clinical improvement control group Cord blood COVID-19 COVID-19 patients dissemination dose Efficacy element Estimated feasibility feasible hospitalised patient immunomodulatory properties infected with SARS-CoV-2 injection intravenous Melbourne, Australia moderate New number objective occur outcome participant Patient Placebo Pneumonia Prevent progression protocol randomised randomised controlled trial RCT recruit recruitment Registered registry Safety Sample size SARS-COV-2 infection sealed severe ARDS severe pneumonia Standard status stem cells Study protocol supportive care therapy Tolerability Total Treatment Trial Umbilical cord umbilical cord blood virus website
[DOI] 10.1186/s13063-020-04387-y PMC 바로가기 [Article Type] Letter

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 95% confidence interval Adjusted analysis Administered Admission age alcohol allocation concealment ALT/AST Analysis Arm arrhythmia assigned Beta block-randomization Blood calculated Care center clinical Clinical improvement clinical trial conducted confirmed case control group cough COVID-19 COVID-19 confirmed patient COVID-19 in patient COVID-2019 Cox proportional-hazards model death discharge disease dissemination drug Duration education Effectiveness element eligibility enrolled excluded exclusion criteria fatigue follow-up time hazard headache Health hospital hospital discharge Hospitalization Hydroxychloroquine + Lopinavir/Ritonavir improvement include Interaction Interferon beta-1a Interferon-β 1a Interferon-β 1b intervals intervention group investigator Kaletra Kaplan–Meier laboratory result lactating women Last limit log-rank test Loghman Hakim Hospital Lopinavir Lopinavir/ritonavir masking mechanical ventilation Medical Science Medical Sciences moderate Mortality myalgia nasal NCT04343768 number objective open label Open-label Other outcome oxygen saturation package parallel group participant Patient performed positive pregnant Primary outcome primary outcome measure problem professional protocol pulse-oximetry R software R version 3.6.1 randomization randomization sequence Randomized Randomized controlled trial Randomly reached receive Recigen recruitment refusal regimen Registered Research respiratory rate RT-PCR test Sample SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale single center single dose SpO2 sputum production standard care status Study protocol Symptom temperature tested the patient therapeutic three groups time treat treated treatment groups Trial university version 3.6.1 website World Health Organization Ziferon
[DOI] 10.1186/s13063-020-04382-3 PMC 바로가기 [Article Type] Letter

A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 age Algorithm anonymously APC Arm avoidance Behavioral intent behavioural blinded changes in clinical component control arm control group country COVID-19 COVID-19 outbreak Developed dissemination Effect Effectiveness Effects element eligible English Entertainment-education excluded expected experiment Face masks female FIVE France French Germany Gorilla highest Host hygiene IMPROVE include Interaction Intervention intervention arm investigator investigators item knowledge List experiment male media Medicine Novel coronavirus number objective outcome outcome measure parallel group participant Participants physical contact Placebo platform Prevalence Prevent Primary outcome Prolific Academic protocol question questionnaire randomised controlled trial randomization randomize Randomized Randomized controlled trial Randomly RCT reached receive recruit recruited reduce Registered secondary outcome sequence Sex social distancing Spain Spanish Spread spread of COVID-19 Stanford Study protocol submitted The United States total sample size Treatment treatment group Trial United Kingdom was collected washing hand washing hands website
[DOI] 10.1186/s13063-020-04449-1 PMC 바로가기 [Article Type] Letter

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 95% CI absence addition administration of hydroxychloroquine Admission aerosol-generating procedures allergy analyzed Anesthesia antibody approved ARMS assigned balanced randomization blind Cancer Cantabria carried CDC Cell Chemoprophylaxis clinical Clinical data clinically coated Committee comparator Comparator group computer-generated control group Controlled Controlled clinical trial Controlled trial coronavirus COVID COVID-19 criteria CURB current detect Determination disease dissemination double blind double-blind dropout rate Efficacy Efficacy and safety element ELISA kit Emergency Endocrine estimate Ethics Euroimmun Evidence evidence of Germany GRADE greater group Health Health authority health-care healthcare personnel Healthcare professional healthcare professionals heart heart failure help hematological high risk hospital Hydroxychloroquine hydroxychloroquine sulfate hygiene Hypothesis ICU IDT IgA IgG IgM and IgG immune immunodeficiency in vitro incidence include Infection inhibit intensive care unit Intervention investigator kidney lactation liver measure Measures Medicine Negative PCR neurological New York number observation period outcome participant PCR performed Personal protective equipment Placebo positive positive SARS-CoV-2 PCR positive serology Pregnancy presenting Prevalence Primary outcome probes product professional Prophylaxis Prospective PROTECT Protective protocol Psychiatric randomised randomised controlled trial randomization Randomized randomized trial RCT receive recruitment reduce reported responsible risk RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR sequence Seroconversion serological serology severity Significant single center single-center study social distancing Spain Spanish Standard Statistical power status Study protocol subject Support Symptom symptomatic and asymptomatic Tablet Takara Taking Tamoxifen Transmission Treatment two-tailed university Vaccine virus website while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter